KalVista Pharmaceuticals (KALV)

KalVista’s lead commercial product is EKTERLY, the brand name for sebetralstat. It is an orally administered small-molecule plasma kallikrein inhibitor approved by the US Food and Drug Administration for the treatment of acute attacks of hereditary angioedema in adults and paediatric patients aged 12 years and older. Hereditary angioedema is a rare genetic condition that can cause unpredictable, painful and potentially life-threatening swelling episodes. By targeting plasma kallikrein, sebetralstat is intended to interrupt the biochemical cascade that drives these attacks.

The oral format is central to KalVista’s positioning. Many HAE therapies have historically required injections or infusions, so an effective tablet-based option can be meaningful for patients seeking rapid and convenient treatment during attacks. The company’s strategy is to apply its medicinal chemistry and rare disease development capabilities to areas where targeted oral inhibitors may replace or complement more burdensome treatment approaches.

KalVista operates in a specialised market where clinical data, regulatory approvals, physician adoption, payer coverage and patient access are key commercial factors. Its prospects are closely linked to the launch and uptake of EKTERLY, as well as the company’s ability to extend its kallikrein-focused platform into additional indications with clear unmet medical need.